Correlation of SARS-CoV-2-breakthrough infections to time-from-vaccine

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works

Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant

Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889 · see citing works

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Dagan, N., Barda, N., Kepten, E., Miron, O., Perchik, S., Katz, M. A., Hernán, M. A., Lipsitch, M., Reis, B., & Balicer, R. D. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2101765 · Cited by 2,527 · see citing works

Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans

Seow, J., Graham, C., Merrick, B., Acors, S., Pickering, S., Steel, K. J. A., Hemmings, O., O’Byrne, A., Kouphou, N., Galao, R. P., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-00813-8 · Cited by 1,419 · see citing works

Covid-19 Breakthrough Infections in Vaccinated Health Care Workers

Bergwerk, M., Gonen, T., Lustig, Y., Amit, S., Lipsitch, M., Cohen, C., Mandelboim, M., Levin, E. G., Rubin, C., Indenbaum, V., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2109072 · Cited by 1,345 · see citing works

Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality

Coresh, J., Turin, T. C., Matsushita, K., Sang, Y., Ballew, S. H., Appel, L. J., Arima, H., Chadban, S. J., Cirillo, M., Djurdjev, O., et al. (2014) · JAMA · doi:10.1001/jama.2014.6634 · Cited by 988 · see citing works

Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum

Liu, C., Ginn, H. M., Dejnirattisai, W., Supasa, P., Wang, B., Tuekprakhon, A., Nutalai, R., Zhou, D., Mentzer, A. J., Zhao, Y., et al. (2021) · Cell · doi:10.1016/j.cell.2021.06.020 · Cited by 669 · see citing works

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe · doi:10.1016/j.chom.2021.04.007 · Cited by 636 · see citing works

Increased Resistance of SARS-CoV-2 Variant P.1 to Antibody Neutralization

(2021) · doi:10.1101/2021.03.01.433466 · Cited by 626 · see citing works

Spike-antibody waning after second dose of BNT162b2 or ChAdOx1

Shrotri, M., Navaratnam, A. M. D., Nguyen, V., Byrne, T., Geismar, C., Fragaszy, E., Beale, S., Fong, W. L. E., Patel, P., Kovar, J., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)01642-1 · Cited by 393 · see citing works

The Effectiveness of the Two-Dose BNT162b2 Vaccine: Analysis of Real-World Data

Chodick, G., Tene, L., Rotem, R. S., Patalon, T., Gazit, S., Ben-Tov, A., Weil, C., Goldshtein, I., Twig, G., Cohen, D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciab438 · Cited by 176 · see citing works

The epidemiology of diabetes in a large Israeli HMO

Chodick, G., Heymann, A. D., Shalev, V., & Kokia, E. S. (2003) · European Journal of Epidemiology · doi:10.1023/b:ejep.0000006635.36802.c8 · Cited by 175 · see citing works

The use of an automated patient registry to manage and monitor cardiovascular conditions and related outcomes in a large health organization

Shalev, V., Chodick, G., Goren, I., Silber, H., Kokia, E. S., & Heymann, A. D. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2010.08.002 · Cited by 153 · see citing works

Neutralising capacity against Delta (B.1.617.2) and other variants of concern following Comirnaty (BNT162b2, BioNTech/Pfizer) vaccination in health care workers, Israel

Lustig, Y., Zuckerman, N. S., Nemet, I., Atari, N., Kliker, L., Regev‐Yochay, G., Sapir, E., Mor, O., Alroy‐Preis, S., Mendelson, E., et al. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.26.2100557 · Cited by 143 · see citing works

BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants

Liu, Y., Liu, J., Xia, H., Zhang, X., Zou, J., Fontes-Garfias, C. R., Weaver, S. C., Swanson, K. A., Cai, H., Sarkar, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2106083 · Cited by 90 · see citing works

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Roest, S., Hoek, R. A. S., & Manintveld, O. C. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2104281 · Cited by 88 · see citing works

Durability of SARS-CoV-2 IgG Antibody Among Residents in a Long-Term Care Community

Ruopp, M. D., Strymish, J. M., Dryjowicz-Burek, J., Creedon, K., & Gupta, K. (2021) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2021.01.066 · Cited by 12 · see citing works

Effectiveness of COVID-19 vaccines against the Omicron (B.1.1.529) variant of concern

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Rickeard, T., Gallagher, E., Gower, C., Kall, M., Groves, N., O’Connell, A.-M., et al. (2021) · doi:10.1101/2021.12.14.21267615 · Cited by 2,420 · see citing works

Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel

Bar-On, Y. M., Goldberg, Y., Mandel, M., Bodenheimer, O., Freedman, L., Kalkstein, N., Mizrahi, B., Alroy-Preis, S., Ash, N., Milo, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114255 · Cited by 1,169 · see citing works

Waning Immunity after the BNT162b2 Vaccine in Israel

Goldberg, Y., Mandel, M., Bar-On, Y. M., Bodenheimer, O., Freedman, L., Haas, E. J., Milo, R., Alroy-Preis, S., Ash, N., & Huppert, A. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114228 · Cited by 1,034 · see citing works

Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar

Chemaitelly, H., Tang, P., Hasan, M. R., AlMukdad, S., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2114114 · Cited by 831 · see citing works

Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines

Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807 · see citing works

Impact of Delta on viral burden and vaccine effectiveness against new SARS-CoV-2 infections in the UK

Pouwels, K. B., Pritchard, E., Matthews, P. C., Stoesser, N., Eyre, D. W., Vihta, K.-D., House, T., Hay, J., Bell, J. I., Newton, J. N., et al. (2021) · doi:10.1101/2021.08.18.21262237 · Cited by 543 · see citing works

Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England

Andrews, N., Stowe, J., Kirsebom, F., Toffa, S., Sachdeva, R., Gower, C., Ramsay, M., & Lopez Bernal, J. (2022) · Nature Medicine · doi:10.1038/s41591-022-01699-1 · Cited by 453 · see citing works

BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar

Tang, P., Hasan, M. R., Chemaitelly, H., Yassine, H. M., Benslimane, F. M., Al Khatib, H. A., AlMukdad, S., Coyle, P., Ayoub, H. H., Al Kanaani, Z., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01583-4 · Cited by 450 · see citing works

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Naturally Acquired Immunity versus Vaccine-induced Immunity, Reinfections versus Breakthrough Infections: A Retrospective Cohort Study

Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben-Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac262 · Cited by 283 · see citing works

Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection

Evans, J. P., Zeng, C., Carlin, C., Lozanski, G., Saif, L. J., Oltz, E. M., Gumina, R. J., & Liu, S. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn8057 · Cited by 235 · see citing works

Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2

Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Katz, R., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2021) · Nature Medicine · doi:10.1038/s41591-021-01575-4 · Cited by 222 · see citing works

COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety

Fendler, A., de Vries, E. G. E., GeurtsvanKessel, C. H., Haanen, J. B. A. G., Wormann, B. J., Turajlic, S., & von Lilienfeld‐Toal, M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00610-8 · Cited by 205 · see citing works

Waning effectiveness of the third dose of the BNT162b2 mRNA COVID-19 vaccine

Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · Nature Communications · doi:10.1038/s41467-022-30884-6 · Cited by 143 · see citing works

Vaccination with BNT162b2 reduces transmission of SARS-CoV-2 to household contacts in Israel

Prunas, O., Warren, J. L., Crawford, F. W., Gazit, S., Patalon, T., Weinberger, D. M., & Pitzer, V. E. (2022) · Science · doi:10.1126/science.abl4292 · Cited by 153 · see citing works

Assessing Acceptability of COVID-19 Vaccine Booster Dose among Adult Americans: A Cross-Sectional Study

Yadete, T., Batra, K., Netski, D. M., Antonio, S., Patros, M. J., & Bester, J. C. (2021) · Vaccines · doi:10.3390/vaccines9121424 · Cited by 153 · see citing works

Waning Effectiveness of the Third Dose of the BNT162b2 mRNA COVID-19 Vaccine

Patalon, T., Saciuk, Y., Peretz, A., Perez, G., Lurie, Y., Maor, Y., & Gazit, S. (2022) · doi:10.1101/2022.02.25.22271494 · Cited by 143 · see citing works

Characterization of the significant decline in humoral immune response six months post‐SARS‐CoV‐2 mRNA vaccination: A systematic review

Notarte, K. I., Guerrero‐Arguero, I., Velasco, J. V., Ver, A. T., de Oliveira, M. H. S., Catahay, J. A., Khan, M. S. R., Pastrana, A. M., Juszczyk, G., Torrelles, J. B., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27688 · Cited by 143 · see citing works

Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine

Patalon, T., Gazit, S., Pitzer, V. E., Prunas, O., Warren, J. L., & Weinberger, D. M. (2022) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2021.7382 · Cited by 141 · see citing works

American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 5

Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42372 · Cited by 120 · see citing works

COVID vaccine boosters: the most important questions

Callaway, E. (2021) · Nature · doi:10.1038/d41586-021-02158-6 · Cited by 109 · see citing works

COVID-19 Vaccine Booster Hesitancy (VBH) of Healthcare Workers in Czechia: National Cross-Sectional Study

Klugar, M., Riad, A., Mohanan, L., & Pokorná, A. (2021) · Vaccines · doi:10.3390/vaccines9121437 · Cited by 109 · see citing works

COVID-19 Vaccine Booster: To Boost or Not to Boost

Shekhar, R., Garg, I., Pal, S., Kottewar, S., & Sheikh, A. B. (2021) · Infectious Disease Reports · doi:10.3390/idr13040084 · Cited by 108 · see citing works

Lower persistence of anti-nucleocapsid compared to anti-spike antibodies up to one year after SARS-CoV-2 infection

Elslande, J. V., Oyaert, M., Lorent, N., Weygaerde, Y. V., Pottelbergh, G. V., Godderis, L., Ranst, M. A. V., André, E., Padalko, E. Y., Lagrou, K., et al. (2022) · Diagnostic Microbiology and Infectious Disease · doi:10.1016/j.diagmicrobio.2022.115659 · Cited by 93 · see citing works

Durability of Vaccine-Induced and Natural Immunity Against COVID-19: A Narrative Review

Pooley, N., Karim, S. S. A., Combadière, B., Ooi, E. E., Harris, R. C., Guerche‐Séblain, C. E., Kisomi, M., & Shaikh, N. (2023) · Infectious Diseases and Therapy · doi:10.1007/s40121-022-00753-2 · Cited by 93 · see citing works

mRNA vaccines against SARS-CoV-2 induce comparably low long-term IgG Fc galactosylation and sialylation levels but increasing long-term IgG4 responses compared to an adenovirus-based vaccine

Buhre, J. S., Pongrácz, T., Künsting, I., Lixenfeld, A. S., Wang, W., Nouta, J., Lehrian, S., Schmelter, F., Lunding, H. B., Dühring, L., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020844 · Cited by 87 · see citing works

Safety and Immunogenicity of the Third Booster Dose with Inactivated, Viral Vector, and mRNA COVID-19 Vaccines in Fully Immunized Healthy Adults with Inactivated Vaccine

Kanokudom, S., Assawakosri, S., Suntronwong, N., Auphimai, C., Nilyanimit, P., Vichaiwattana, P., Thongmee, T., Yorsaeng, R., Srimuan, D., Thatsanatorn, T., et al. (2022) · Vaccines · doi:10.3390/vaccines10010086 · Cited by 82 · see citing works

Short term, relative effectiveness of four doses versus three doses of BNT162b2 vaccine in people aged 60 years and older in Israel: retrospective, test negative, case-control study

Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Pitzer, V. E., & Patalon, T. (2022) · BMJ · doi:10.1136/bmj-2022-071113 · Cited by 87 · see citing works

SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort

Aldridge, R. W., Yavlinsky, A., Nguyen, V. G., Eyre, M. T., Shrotri, M., Navaratnam, A. M. D., Beale, S., Braithwaite, I., Byrne, T., Kovar, J., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32265-5 · Cited by 83 · see citing works

Relative infectiousness of SARS-CoV-2 vaccine breakthrough infections, reinfections, and primary infections

Abu-Raddad, L. J., Chemaitelly, H. S., Ayoub, H. H., Tang, P., Coyle, P. V., Hasan, M. R., Yassine, H. M., Benslimane, F. M., Al-Khatib, H. A., Kanaani, Z. A., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28199-7 · Cited by 79 · see citing works

Long-term immunogenicity of BNT162b2 vaccination in the elderly and in younger health care workers

Tober-Lau, P., Schwarz, T., Vanshylla, K., Hillus, D., Gruell, H., EICOV/COVIM Study Group, Suttorp, N., Landgraf, I., Kappert, K., Seybold, J., et al. (2021) · doi:10.1101/2021.08.26.21262468 · Cited by 69 · see citing works

American College of Rheumatology Guidance for COVID ‐19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 4

Curtis, J. R., Johnson, S. R., Anthony, D. D., Arasaratnam, R. J., Baden, L. R., Bass, A. R., Calabrese, C. M., Gravallese, E. M., Harpaz, R., Kroger, A. T., et al. (2022) · Arthritis & Rheumatology · doi:10.1002/art.42109 · Cited by 68 · see citing works

Charge‐Polarized Selenium Vacancy in Nickel Diselenide Enabling Efficient and Stable Electrocatalytic Conversion of Oxygen to Hydrogen Peroxide

Wang, Y., Huang, H., Wu, J., Yang, H., Kang, Z., Liu, Y., Wang, Z., Menezes, P. W., & Chen, Z. (2022) · Advanced Science · doi:10.1002/advs.202205347 · Cited by 67 · see citing works

Waning of SARS-CoV-2 booster viral-load reduction effectiveness

Levine-Tiefenbrun, M., Yelin, I., Alapi, H., Herzel, E., Kuint, J., Chodick, G., Gazit, S., Patalon, T., & Kishony, R. (2022) · Nature Communications · doi:10.1038/s41467-022-28936-y · Cited by 63 · see citing works

Multiple COVID-19 Waves and Vaccination Effectiveness in the United States

Lin, L., Zhao, Y., Chen, B., & He, D. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042282 · Cited by 61 · see citing works

Can a combination of vaccination and face mask wearing contain the COVID‐19 pandemic?

Brüssow, H., & Zuber, S. (2021) · Microbial Biotechnology · doi:10.1111/1751-7915.13997 · Cited by 61 · see citing works

Seroresponse to SARS-CoV-2 Vaccines among Maintenance Dialysis Patients over 6 Months

Hsu, C. M., Weiner, D. E., Manley, H. J., Aweh, G. N., Ladik, V., Frament, J., Miskulin, D., Agyropoulos, C., Abreo, K. D., Chin, A., et al. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12250921 · Cited by 61 · see citing works

Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial

Bonelli, M. M., Mrak, D., Tobudic, S., Sieghart, D., Koblischke, M., Mandl, P., Kornek, B., Simader, E., Radner, H., Perkmann, T., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-221558 · Cited by 59 · see citing works

The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine

Gazit, S., Shlezinger, R., Perez, G., Lotan, R., Peretz, A., Ben‐Tov, A., Herzel, E., Alapi, H., Cohen, D., Muhsen, K., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m21-4130 · Cited by 56 · see citing works

Covid-19 booster vaccines: What we know and who’s doing what

Mahase, E. (2021) · BMJ · doi:10.1136/bmj.n2082 · Cited by 55 · see citing works

Trajectory of IgG to SARS-CoV-2 After Vaccination With BNT162b2 or mRNA-1273 in an Employee Cohort and Comparison With Natural Infection

Keshavarz, B., Richards, N. E., Workman, L. J., Patel, J., Muehling, L. M., Canderan, G., Murphy, D. D., Brovero, S. G., Ailsworth, S. M., Eschenbacher, W. H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.850987 · Cited by 54 · see citing works

Covid-19: virology, variants, and vaccines

Young, M., Crook, H., Scott, J. T., & Edison, P. (2022) · BMJ Medicine · doi:10.1136/bmjmed-2021-000040 · Cited by 52 · see citing works

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses

Lapointe, H. R., Mwimanzi, F. M., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Speckmaier, S., Moran-Garcia, N., Datwani, S., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac229 · Cited by 54 · see citing works

mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron

Lee, H., Knabl, L., Moliva, J. I., Knabl, L., Werner, A. P., Boyoglu-Barnum, S., Kapferer, S., Pateter, B., Walter, M., Sullivan, N. J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110680 · Cited by 47 · see citing works

Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients

Benning, L., Morath, C. P., Bartenschlager, M., Kim, H., Reineke, M., Beimler, J., Buylaert, M., Nußhag, C., Kälble, F., Reichel, P., et al. (2022) · American Journal of Transplantation · doi:10.1111/ajt.17054 · Cited by 49 · see citing works

Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status

Yu, E. D., Wang, E. W., Garrigan, E., Goodwin, B., Sutherland, A., Tarke, A., Chang, J., Gálvez, R. I., Mateus, J., Ramirez, S. I., et al. (2022) · Cell Host & Microbe · doi:10.1016/j.chom.2022.02.003 · Cited by 45 · see citing works

Risk of SARS-CoV-2 reinfections in children: a prospective national surveillance study between January, 2020, and July, 2021, in England

Mensah, A. A., Campbell, H. J., Stowe, J., Seghezzo, G., Simmons, R., Lacy, J., Bukasa, A., O’Boyle, S., Ramsay, M. E., Brown, K. E., et al. (2022) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00059-1 · Cited by 49 · see citing works

Humoral immune response of BBIBP COVID‐19 vaccination before and after the booster immunization

Cheng, Z. J., Huang, H., Zheng, P., Xue, M., Ma, J., Zhan, Z., Gan, H., Zeng, Y., Lin, R., Li, S., et al. (2022) · Allergy · doi:10.1111/all.15271 · Cited by 48 · see citing works

Effectiveness of inactivated COVID-19 vaccines against severe illness in B.1.617.2 (Delta) variant–infected patients in Jiangsu, China

Hu, Z., Tao, B., Li, Z., Song, Y., Yi, C., Li, J., Zhu, M., Yi, Y., Huang, P., & Wang, J. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.01.030 · Cited by 47 · see citing works

Testing Fractional doses of COVID-19 Vaccines

Więcek, W., Ahuja, A., Chaudhuri, E., Kremer, M. R., Gomes, A. S., Snyder, C. M., Tabarrok, A. T., & Tan, B. J. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2116932119 · Cited by 43 · see citing works

Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines

Hvidt, A. K., Baerends, E. A. M., Søgaard, O. S., Stærke, N. B., Raben, D., Reekie, J., Nielsen, H., Johansen, I. S., Wiese, L., Benfield, T., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.994160 · Cited by 41 · see citing works

Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

McKeigue, P., McAllister, D., Hutchinson, S. J., Robertson, C., Stockton, D., & Colhoun, H. M. (2022) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(22)00045-5 · Cited by 44 · see citing works

Factors Affecting Initial Humoral Immune Response to SARS-CoV-2 Vaccines Among Patients With Inflammatory Bowel Diseases

Kappelman, M. D., Weaver, K. N., Zhang, X., Dai, X., Watkins, R. D., Adler, J., Dubinsky, M. C., Kastl, A., Bousvaros, A., Strople, J. A., et al. (2021) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000001619 · Cited by 43 · see citing works

GRT-R910: a self-amplifying mRNA SARS-CoV-2 vaccine boosts immunity for ≥6 months in previously-vaccinated older adults

Palmer, C. D., Scallan, C. D., Kraemer Tardif, L. D., Kachura, M. A., Rappaport, A. R., Koralek, D. O., Uriel, A., Gitlin, L., Klein, J., Davis, M. J., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-39053-9 · Cited by 42 · see citing works

Risk of Vaccine Breakthrough SARS-CoV-2 Infection and Associated Factors in Healthcare Workers of Trieste Teaching Hospitals (North-Eastern Italy)

Basso, P., Negro, C., Cegolon, L., & Filon, F. L. (2022) · Viruses · doi:10.3390/v14020336 · Cited by 41 · see citing works

A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines

He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 40 · see citing works

Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose

Mwimanzi, F. M., Lapointe, H. R., Cheung, P. K., Sang, Y., Yaseen, F., Umviligihozo, G., Kalikawe, R., Datwani, S., Omondi, F. H., Burns, L., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac199 · Cited by 39 · see citing works

Humoral and T-Cell Immune Response After 3 Doses of Messenger RNA Severe Acute Respiratory Syndrome Coronavirus 2 Vaccines in Fragile Patients: The Italian VAX4FRAIL Study

Corradini, P., Agrati, C., Apolone, G., Mantovani, A., Giannarelli, D., Marasco, V., Bordoni, V., Sacchi, A., Matusali, G., Salvarani, C., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac404 · Cited by 39 · see citing works

Diminished and waning immunity to COVID-19 vaccination among hemodialysis patients in Israel: the case for a third vaccine dose

Angel-Korman, A., Peres, E., Bryk, G., Lustig, Y., Indenbaum, V., Amit, S., Rapoport, V., Katzir, Z., Yagil, Y., Iaina, N. L., et al. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab206 · Cited by 37 · see citing works

Predictors of COVID-19 booster vaccine hesitancy among fully vaccinated adults in Korea: a nationwide cross-sectional survey

Noh, Y., Kim, J. H., Yoon, D., Choe, Y. J., Choe, S., Jung, J., Lee, S., & Shin, J. (2022) · Epidemiology and Health · doi:10.4178/epih.e2022061 · Cited by 35 · see citing works

IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers

Decru, B., Elslande, J. V., Steels, S., Pottelbergh, G. V., Godderis, L., Holm, B. V., Bossuyt, X., Weyenbergh, J. V., Maes, P., & Vermeersch, P. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.909910 · Cited by 33 · see citing works

Reduced immunogenicity of BNT162b2 booster vaccination in combination with a tetravalent influenza vaccination: results of a prospective cohort study in 838 health workers

Radner, H., Sieghart, D., Jorda, A., Fedrizzi, C., Hasenoehrl, T., Zdravkovic, A., Redlberger‐Fritz, M., Puchammer-Stoeckl, E., Anderle, K., Bergmann, F., et al. (2022) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2022.12.008 · Cited by 34 · see citing works

The Immune Response to SARS-CoV-2 and Variants of Concern

Torbati, E., Krause, K. L., & Ussher, J. E. (2021) · Viruses · doi:10.3390/v13101911 · Cited by 32 · see citing works

Broad Neutralization of SARS-CoV-2 Variants, Including Omicron, following Breakthrough Infection with Delta in COVID-19-Vaccinated Individuals

Lechmere, T., Snell, L. B., Graham, C., Seow, J., Shalim, Z. A., Charalampous, T., Alcolea-Medina, A., Batra, R., Nebbia, G., Edgeworth, J. D., et al. (2022) · mBio · doi:10.1128/mbio.03798-21 · Cited by 30 · see citing works

Vaccine effectiveness against onward transmission of SARS-CoV2-infection by variant of concern and time since vaccination, Belgian contact tracing, 2021

Braeye, T., Catteau, L., Brondeel, R., van Loenhout, J. A. F., Proesmans, K., Cornelissen, L., Oyen, H. J. V., Stouten, V., Hubin, P., Billuart, M., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.04.025 · Cited by 33 · see citing works

The association between social media use and hesitancy toward COVID-19 vaccine booster shots in China: A web-based cross-sectional survey

Wang, R., Qin, C., Du, M., Liu, Q., Tao, L., & Liu, J. (2022) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2022.2065167 · Cited by 32 · see citing works

Humoral Immunogenicity of 3 COVID-19 Messenger RNA Vaccine Doses in Patients With Inflammatory Bowel Disease

Schell, T. L., Knutson, K. L., Saha, S., Wald, A. M., Phan, H., Almasry, M., Chun, K., Grimes, I. C., Lutz, M. K., Hayney, M. S., et al. (2022) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izac082 · Cited by 32 · see citing works

Echinacea Purpurea For the Long-Term Prevention of Viral Respiratory Tract Infections During Covid-19 Pandemic: A Randomized, Open, Controlled, Exploratory Clinical Study

Kolev, E., Mircheva, L., Edwards, M. R., Johnston, S. L., Kalinov, K., Stange, R., Gancitano, G., Berghe, W. V., & Kreft, S. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856410 · Cited by 31 · see citing works

COVID-19 forecasting using new viral variants and vaccination effectiveness models

Rashed, E. A., Kodera, S., & Hirata, A. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105986 · Cited by 31 · see citing works

Associations of vaccine status with characteristics and outcomes of hospitalized severe COVID-19 patients in the booster era

Freund, O., Tau, L., Weiss, T. E., Zornitzki, L., Frydman, S., Jacob, G., & Bornstein, G. (2022) · PLoS ONE · doi:10.1371/journal.pone.0268050 · Cited by 30 · see citing works

SARS-CoV-2 Breakthrough Infections: Incidence and Risk Factors in a Large European Multicentric Cohort of Health Workers

Porru, S., Monaco, M. G. L., Spiteri, G., Carta, A., Pezzani, M. D., Lippi, G., Gibellini, D., Tacconelli, E., Vecchia, I. D., Sala, E., et al. (2022) · Vaccines · doi:10.3390/vaccines10081193 · Cited by 30 · see citing works

Comparative effectiveness of mRNA-1273 and BNT162b2 against symptomatic SARS-CoV-2 infection

Puranik, A., Lenehan, P. J., Silvert, E., Niesen, M. J. M., Corchado-García, J., O’Horo, J. C., Virk, A., Swift, M. D., Gordon, J. E., Speicher, L. L., et al. (2021) · Med · doi:10.1016/j.medj.2021.12.002 · Cited by 30 · see citing works

Estimation of Real-World Vaccination Effectiveness of mRNA COVID-19 Vaccines against Delta and Omicron Variants in Japan

Kodera, S., Rashed, E. A., & Hirata, A. (2022) · Vaccines · doi:10.3390/vaccines10030430 · Cited by 28 · see citing works

Waning of 2-dose BNT162b2 and mRNA-1273 vaccine effectiveness against symptomatic SARS-CoV-2 infection accounting for depletion-of-susceptibles bias

Andrejko, K. L., Pry, J. M., Myers, J. F., Mehrotra, M., Lamba, K., Lim, E., Fukui, N., DeGuzman, J. L., Openshaw, J., Watt, J., et al. (2023) · American Journal of Epidemiology · doi:10.1093/aje/kwad017 · Cited by 28 · see citing works

Nucleic acid delivery and nanoparticle design for COVID vaccines

Andresen, J. L., & Fenton, O. S. (2021) · MRS Bulletin · doi:10.1557/s43577-021-00169-2 · Cited by 29 · see citing works

Evaluation of Transplacental Antibody Transfer in SARS-CoV-2-Immunized Pregnant Women

Shen, C., Fu, Y.-C., Lin, Y.-P., Shen, C., Sun, D.-J., Shen, C., & Cheng, C. (2022) · Vaccines · doi:10.3390/vaccines10010101 · Cited by 27 · see citing works

Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing

Rea, I. M., & Alexander, H. D. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101494 · Cited by 27 · see citing works

COVID-19 breakthrough infections and humoral immune response among BNT162b2 vaccinated healthcare workers in Malaysia

Yang, S. L., Ripen, A. M., Leong, C. T., Lee, J. V., Yen, C. H., Chand, A. K., Koh, K., Rahim, N. A. B. A., Gokilavanan, V., Mohamed, N. N. E., et al. (2022) · Emerging Microbes & Infections · doi:10.1080/22221751.2022.2065936 · Cited by 27 · see citing works

COVID-19 Breakthrough Infection after Inactivated Vaccine Induced Robust Antibody Responses and Cross-Neutralization of SARS-CoV-2 Variants, but Less Immunity against Omicron

Suntronwong, N., Yorsaeng, R., Puenpa, J., Auphimai, C., Thongmee, T., Vichaiwattana, P., Kanokudom, S., Duangchinda, T., Chantima, W., Pakchotanon, P., et al. (2022) · Vaccines · doi:10.3390/vaccines10030391 · Cited by 24 · see citing works

The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center

Skrzat‐Klapaczyńska, A., Bieńkowski, C., Kowalska, J. D., Paciorek, M., Puła, J., Krogulec, D., Stengiel, J., Pawełczyk, A., Perlejewski, K., Osuch, S., et al. (2022) · Vaccines · doi:10.3390/vaccines10040552 · Cited by 26 · see citing works

Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation

Gazit, S., Saciuk, Y., Perez, G., Peretz, A., Ben‐Tov, A., Stuart, E. A., & Patalon, T. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(23)00103-9 · Cited by 24 · see citing works

Multi-antigen intranasal vaccine protects against challenge with sarbecoviruses and prevents transmission in hamsters

Leekha, A., Saeedi, A., Sefat, K. M. S. R., Kumar, M., Martinez-Paniagua, M. A., Damian, A., Kulkarni, R. S., Reichel, K., Rezvan, A., Masoumi, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50133-2 · Cited by 25 · see citing works

Variant-specific vaccination induces systems immune responses and potent in vivo protection against SARS-CoV-2

Peng, L., Renauer, P. A., Ökten, A., Fang, Z., Park, J. J., Zhou, X., Lin, Q., Dong, M. B., Filler, R., Xiong, Q., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100634 · Cited by 21 · see citing works

Mosaic RBD nanoparticles induce intergenus cross-reactive antibodies and protect against SARS-CoV-2 challenge

Lee, D. B., Kim, H., Jeong, J. H., Jang, U. S., Jang, Y., Roh, S., Jeon, H., Kim, E. J., Han, S. Y., Maeng, J. Y., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2208425120 · Cited by 22 · see citing works

Kinetics of vaccine-induced neutralizing antibody titers and estimated protective immunity against wild-type SARS-CoV-2 and the Delta variant: A prospective nationwide cohort study comparing three COVID-19 vaccination protocols in South Korea

Nham, E., Ko, J., Song, K., Choi, J., Kim, E. S., Kim, H., Kim, B., Lim, H.-Y., Kim, K.-C., Jang, H., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.968105 · Cited by 22 · see citing works

UVC-Based Air Disinfection Systems for Rapid Inactivation of SARS-CoV-2 Present in the Air

Garg, H., Ringe, R. P., Das, S., Parkash, S., Thakur, B., Delipan, R., Kumar, A., Kulkarni, K. S., Bansal, K., Patil, P. B., et al. (2023) · Pathogens · doi:10.3390/pathogens12030419 · Cited by 22 · see citing works

Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2

Clairon, Q., Prague, M., Planas, D., Bruel, T., Hocqueloux, L., Prazuck, T., Schwartz, O., Thiébaut, R., & Guedj, J. (2023) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1011282 · Cited by 22 · see citing works

Assessing the risk of vaccine-driven virulence evolution in SARS-CoV-2

Miller, I. F., & Metcalf, C. J. E. (2022) · Royal Society Open Science · doi:10.1098/rsos.211021 · Cited by 22 · see citing works

Effectiveness of COVID-19 Vaccines against Delta Variant (B.1.617.2): A Meta-Analysis

Mahumud, R. A., Ali, M. A., Kundu, S., Rahman, M. A., Kamara, J. K., & Renzaho, A. M. N. (2022) · Vaccines · doi:10.3390/vaccines10020277 · Cited by 20 · see citing works

SARS‐CoV‐2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine

Yavuz, E., Günal, Ö., Başbulut, E., & Şen, A. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27794 · Cited by 20 · see citing works

Clinical characteristics and immune profile alterations in vaccinated individuals with breakthrough Delta SARS-CoV-2 infections

Fan, Q., Shi, J., Yang, Y., Tang, G., Jiang, M., Li, J. J., Tang, J., Li, L., Wen, X., Zhang, L., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-31693-7 · Cited by 19 · see citing works

Short-Term Adverse Effects Immediately after the Start of COVID-19 Booster Vaccination in Vietnam

Nguyen, D. C., Dao, T. L., Truong, T. M. D., Nguyen, T. H., Phan, T. N., Nguyen, M. H., Pham, T. D., Nguyen, X. B., Nguyen, T. B., & Hoang, V. T. (2022) · Vaccines · doi:10.3390/vaccines10081325 · Cited by 20 · see citing works

Changing Patterns of SARS-CoV-2 Seroprevalence among Canadian Blood Donors during the Vaccine Era

Reedman, C. N., Drews, S. J., Yi, Q., Pambrun, C., & O’Brien, S. F. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00339-22 · Cited by 20 · see citing works

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac315 · Cited by 19 · see citing works

Association of BNT162b2 Vaccine Third Dose Receipt With Incidence of SARS-CoV-2 Infection, COVID-19–Related Hospitalization, and Death Among Residents of Long-term Care Facilities, August to October 2021

Muhsen, K., Maimon, N., Mizrahi, A., Varticovschi, B., Bodenheimer, O., Cohen, D., & Dagan, R. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.19940 · Cited by 19 · see citing works

Prevalence and Disability-Adjusted Life Year Rates of Asthma in China: Findings from the GBD Study 2019 of the G20

Liu, M., Gan, H., Lin, Y., Lin, R., Xue, M., Zhang, T., Cheng, Z. J., & Sun, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192214663 · Cited by 19 · see citing works

Behavioral Intention and Its Predictors toward COVID-19 Booster Vaccination among Chinese Parents: Applying Two Behavioral Theories

Zhou, M., Liu, L., Gu, S., Peng, X., Zhang, C., Wu, Q.-F., Xu, X., & You, H. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127520 · Cited by 18 · see citing works

In vitro inhibition of SARS-CoV-2 Infection by dry algae powders

García-Ruíz, D., Villalobos-Sánchez, E., Alam-Escamilla, D., & Elizondo‐Quiroga, D. (2022) · Scientific Reports · doi:10.1038/s41598-022-22148-6 · Cited by 18 · see citing works

Threshold conditions for curbing COVID-19 with a dynamic zero-case policy derived from 101 outbreaks in China

Tang, S., Wang, X., Tang, B., He, S., Yan, D., Huang, C., Shao, Y., Xiao, Y., & Cheke, R. (2023) · BMC Public Health · doi:10.1186/s12889-023-16009-8 · Cited by 18 · see citing works

COVID-19 booster uptake among US adults: Assessing the impact of vaccine attributes, incentives, and context in a choice-based experiment

Raman, S., Kriner, D. L., Ziebarth, N. R., Simon, K. I., & Kreps, S. E. (2022) · Social Science & Medicine · doi:10.1016/j.socscimed.2022.115277 · Cited by 18 · see citing works

Change in covid-19 risk over time following vaccination with CoronaVac: test negative case-control study

Hitchings, M. D. T., Ranzani, O., Lind, M. L., Dorión, M., D’Agostini, T. L., de Paula, R. C., de Paula, O. F. P., Villela, E. F. D. M., Torres, M. S. S., de Oliveira, S. B., et al. (2022) · BMJ · doi:10.1136/bmj-2022-070102 · Cited by 18 · see citing works

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in AdolescentsPreprint

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · medRxiv · doi:10.1101/2022.01.04.22268776 · Cited by 16 · see citing works

Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals

Kustin, T., Harel, N., Finkel, U., Perchik, S., Harari, S., Tahor, M., Caspi, I., Levy, R., Leshchinsky, M., Ken Dror, S., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01413-7 · Cited by 373 · see citing works

Waning Effectiveness of the BNT162b2 Vaccine Against Infection in Adolescents in Israel

Prunas, O., Weinberger, D. M., Pitzer, V. E., Gazit, S., & Patalon, T. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac315 · Cited by 19 · see citing works

P-2061. Long-term Follow Up of Pfizer-BioNTech BNT162b2 mRNA Vaccinations Reveals Persistent Disparities between SARS-CoV-2 Naive and Infected Individuals in the Context of Breakthrough Infections

Marklund, E., Lundgren, A., Bemark, M., Nyström, K., Li, Y., Yilmaz, A., Andersson, L., & Gisslén, M. (2025) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofae631.2217

Long-Term Comparative Effectiveness of BNT162b2 Vaccine on SARS-CoV-2 Infection in Adolescents. A Register-Based Real-World Study from DenmarkPreprint

Cajar, M. D., Andersen, M. P., Krogager, M. L., Schou, M., Kragholm, K. H., Fosbøl, E. L., Køber, L., & Torp-Pedersen, C. T. (2023) · SSRN Electronic Journal · doi:10.2139/ssrn.4399760